How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing
This article analyzes Enliven Therapeutics Inc. (ELVN) using AI models to provide trading strategies and signals. It notes a near-term neutral sentiment for ELVN, contrasting with mid- and long-term strength, and presents specific institutional trading strategies including position trading, momentum breakout, and risk hedging with defined entry, target, and stop-loss zones. The analysis also highlights a significant risk-reward short setup.
If You Invested $1,000 in Enliven Therapeutics Inc (ELVN)
This article examines the historical performance of investing $1,000 in Enliven Therapeutics Inc (ELVN) over various timeframes, detailing the significant returns an investor would have seen. It also provides an in-depth company profile, outlining Enliven Therapeutics' focus on precision oncology, its lead clinical program ELVN-001 for chronic myeloid leukemia, and key corporate and financial information. The piece highlights Enliven's development trajectory and its strategic position within the biopharmaceutical landscape.
ELVN Maintained by Stifel -- Price Target Raised to $80
Stifel maintained a "Buy" rating for Enliven Therapeutics (ELVN) and raised its price target from $60 to $80 on July 1, 2026, indicating optimism about the company's future. Despite this positive analyst outlook, ELVN has a low GF Score™ of 28/100, primarily due to weak profitability, and has seen significant insider selling totaling $52.9 million in the last three months. Investors should consider both the positive analyst sentiment and these potential risks.
Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com
Jones Trading has increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $70 from $45, reiterating a Buy rating. This adjustment follows a positive Phase I trial update for ELVN-001 in chronic myeloid leukemia (CML) and the company's decision to pursue first-line and second-line-plus CML settings in Phase III trials. Enliven's stock has surged 214% in six months, and the firm estimates significant peak sales potential for ELVN-001 in CML treatment.
Jones Trading raises Enliven Therapeutics price target on CML trials
Jones Trading increased its price target for Enliven Therapeutics (NASDAQ:ELVN) from $45 to $70, while maintaining a Buy rating, based on a positive Phase I update for its CML trials. The biotech company's stock has surged 214% in six months, and Jones Trading revised its model to include first-line and second-line-plus chronic myeloid leukemia settings for two Phase III trials. Despite being deemed overvalued by InvestingPro, the company holds a strong balance sheet and recently raised $460 million in a public offering.
Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com
Jones Trading has increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $70 from $45, reiterating a Buy rating due to impressive Phase I trial results for CML. The biotech firm plans to pursue first-line and second-line-plus chronic myeloid leukemia settings in two Phase III trials, with estimated worldwide peak sales of $4.5 billion by 2036 and $4.6 billion by 2040 for its ELVN-001 drug. This follows a successful public offering that raised approximately $460 million and positive Phase 1 ENABLE trial results showing a 61% overall major molecular response in leukemia patients.
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
OrbiMed Advisors, a significant shareholder in Enliven Therapeutics (NASDAQ: ELVN), recently sold 860,123 shares worth approximately $39 million. This sale represents an 11.60% reduction in their indirect holdings but still leaves OrbiMed as a major shareholder with over 6.5 million shares, indicating continued confidence despite taking profits after a 130% stock rally. Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule kinase inhibitors for cancer, with promising clinical trial results and a strong cash position.
Enliven Therapeutics, Inc. Actuals & Estimates (NASDAQ:ELVN)
This article provides an overview of Enliven Therapeutics, Inc. (NASDAQ: ELVN) stock performance, financial data, and analyst forecasts. It includes current stock price, historical highs and lows, market capitalization, earnings per share, revenue, and upcoming earnings report dates. The company's stock has shown significant increases recently, and analysts have provided future price estimates.
ELVN Forecast — Price Target — Prediction for 2027
This article provides a forecast and various financial metrics for Enliven Therapeutics, Inc. (ELVN) stock. It includes analyst price targets, historical price performance, volatility, market capitalization, upcoming earnings dates, and past financial results like EPS and revenue. The article also addresses frequently asked questions regarding ELVN stock's current price, ticker, growth, and how to invest.
22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here
Enliven Therapeutics (ELVN) is currently valued at US$2.9 billion with shares at US$49.12, showing strong recent performance. Despite being loss-making and having a value score of 2, its Price-to-Book ratio of 6.6x is below its peer average but significantly above the broader US pharmaceuticals industry. This suggests the market has high expectations for its pipeline, making its current valuation dependent on successful clinical trial outcomes.
OrbiMed funds trim Enliven Therapeutics (NASDAQ: ELVN) stake with 860K-share sale
OrbiMed-affiliated entities have reduced their stake in Enliven Therapeutics (NASDAQ: ELVN) by selling 860,123 shares on June 22, 2026, at prices ranging from $45 to $45.38 per share. Despite this sale, the funds still retain significant indirect holdings, with one fund holding over 6.6 million shares and another holding more than 220,000 shares. The transactions were reported in a Form 4 SEC filing, clarifying that these are fund activities rather than personal insider sales by individuals at OrbiMed.
OrbiMed entities sell $39 million in Enliven Therapeutics stock
OrbiMed entities, including OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital GP VII LLC, sold approximately $39 million worth of Enliven Therapeutics (NASDAQ:ELVN) common stock on June 22, 2026. The sale involved 860,123 shares at prices between $45.00 and $45.38, occurring as Enliven's stock was trading near its 52-week high and appeared overvalued according to InvestingPro. Despite the sale, OrbiMed entities collectively retain over 6.7 million shares, and Enliven recently completed an upsized public offering and reported positive Phase 1 trial results for its leukemia drug candidate, ELVN-001.
OrbiMed cuts Enliven Therapeutics (ELVN) holdings to 9.5% of shares
OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Enliven Therapeutics (ELVN) to 9.5% of outstanding shares, as reported in an Amendment No. 5 to their Schedule 13D filing. This reduction stems from open-market sales of Enliven shares by OPI VII, Genesis, and BIOG on June 22, 2025, at prices of $45.38 and $45.00 per share. The filing indicates that OrbiMed may continue to adjust its holdings based on market conditions but currently has no specific plans for corporate control or strategic actions with the issuer.
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
Orbimed Advisors, a medical and biotech-focused hedge fund, recently sold 281,408 shares of Enliven Therapeutics Inc. (ELVN) for approximately $12.67 million, representing 3.67% of its indirect holdings. This transaction follows the biotech company's announcement of promising data for a leukemia drug and comes after a previous significant sale, though Orbimed maintains a substantial investment in Enliven. Investors are left to consider whether the sale is a profit-taking move after a stock rally or due to a revised outlook on the company's future prospects.
ETFs Investing in Enliven Therapeutics, Inc. Stocks
This article lists various ETFs that invest in Enliven Therapeutics, Inc. (ELVN) stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, and assets under management for each fund. The ETFs primarily focus on small-cap, health care, and biotechnology sectors, offering investors diversified exposure to ELVN. The data presented aims to help investors identify suitable funds for investing in ELVN stocks with potentially lower risk.
Enliven Therapeutics stock hits 52-week high at 48.55 USD
Enliven Therapeutics Inc. has achieved a significant milestone, with its stock reaching a 52-week high of $48.55 and currently trading at $48.72, boasting a 198% year-to-date return. This strong performance is supported by recent successful public offerings totaling around $460 million and positive Phase 1 trial results for its leukemia drug candidate, ELVN-001. The company's stock has seen a 127.98% increase over the past year, signaling robust investor confidence and growth prospects.
Enliven Therapeutics stock hits 52-week high at 48.55 USD
Enliven Therapeutics Inc. (ELVN) has reached a new 52-week high of $48.55, reflecting a significant year-to-date return of 198% and a 1-year gain of 127.98%. Despite this strong performance, InvestingPro analysis suggests the stock is overvalued. The company recently closed an upsized public offering, raising approximately $460 million, and reported positive Phase 1 trial results for its leukemia drug candidate, ELVN-001.
Enliven Therapeutics CFO Hohl sells $263,577 in stock
Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of the company's common stock for $263,577 on June 17, 2026, executed under a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high, generating a 193% year-to-date return. Prior to the sale, Hohl exercised stock options to acquire the same number of shares.
Enliven Therapeutics (ELVN) CFO sells 6,018 shares after option exercise
Enliven Therapeutics (ELVN) CFO Benjamin Hohl exercised stock options for 6,018 shares at $2.48 each and subsequently sold all 6,018 shares in open-market transactions on June 17, 2026, at weighted average prices between $42.79 and $44.75. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2026. Following these sales, Hohl maintains a direct holding of 51,000 shares in the company.
The Biotech Growth Trust PLC (ELVN) lists brokered sale of 29,385 shares
The Biotech Growth Trust PLC (ELVN) has filed a Form 144, indicating proposed brokered sales of 29,385 shares through Jefferies LLC and 1,747 shares through Morgan Stanley & Co. LLC. The filing also reports a prior sale of 10,243 shares on June 15, 2026, for $461,139.86. These proposed sales are considered modest relative to the 69,822,989 shares outstanding as of June 22, 2026.
Form 4 Enliven Therapeutics Inc For: 22 June By Investing.com
This article from Investing.com announces the filing of a Form 4 for Enliven Therapeutics Inc. on June 22. It is a brief, one-line report with a reference to Reuters. The article includes various market data, news headlines, and promotional content from Investing.com.
Enliven Therapeutics CMO sells $219,016 in shares
Helen Louise Collins, CMO of Enliven Therapeutics (NASDAQ:ELVN), sold 4,900 shares for $219,016 on June 17, 2026, executed under a Rule 10b5-1 trading plan. These sales followed the exercise of stock options for 5,000 shares. The company's stock is trading near its 52-week high after significant gains, with InvestingPro suggesting it is overvalued.
Enliven Therapeutics (ELVN) CMO exercises 5,000 options and sells 5,000 shares
Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised 5,000 stock options at $2.48 per share and subsequently sold 5,000 shares of common stock in three open-market transactions on June 17, 2026. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, with weighted average prices ranging from $42.8270 to $44.7430 per share. Following these transactions, Collins holds 30,000 direct shares and 121,268 stock options.
Polar Capital (NASDAQ: ELVN) reports 8.46% stake in Enliven Therapeutics
Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported an 8.46% beneficial ownership stake in Enliven Therapeutics (NASDAQ: ELVN). This stake amounts to 5,056,807 shares of common stock, based on Enliven Therapeutics' 60,904,946 outstanding shares as reported in their May 7, 2026, 10-Q filing. The updated ownership was disclosed in an amended Schedule 13G/A filing signed by Nicholas Farren on June 19, 2026.
Enliven Therapeutics (Nasdaq:ELVN) - Stock Analysis
Enliven Therapeutics (Nasdaq:ELVN) is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer treatment, with its lead candidate ELVN-001 showing promising Phase 1 data for chronic myeloid leukemia (CML). The company recently completed a substantial equity offering and gained FDA alignment for a Phase 3 trial of ELVN-001, planned for the second half of 2026. Despite insider selling and current unprofitability, analysts project revenue growth, though some caution about its valuation relative to its commercial prospects.
OrbiMed, Enliven Therapeutics (ELVN) stake now 7.63M shares
OrbiMed has updated its stake in Enliven Therapeutics (ELVN) to 7.63 million shares, representing 10.93% of the company's outstanding common stock. This update is based on an SEC filing (SCHEDULE 13D/A) and reflects a decrease in OrbiMed's beneficial ownership percentage by over 1% due to recent transactions and an increase in Enliven's outstanding shares. The holdings are distributed across several OrbiMed investment vehicles, including OrbiMed Private Investments VII, LP, OrbiMed Genesis Master Fund, L.P., and The Biotech Growth Trust PLC.
Enliven Therapeutics Inc (ELVN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Enliven Therapeutics Inc (ELVN), detailing analyst ratings, price targets, and historical and projected EPS and revenue figures. Based on 12 analysts, the stock receives a "Buy" rating with an average target price of $59.60, representing a 40.07% upside. The article also notes the company's past EPS performance and expectations for the next quarter.
Orbimed sells $12.7m in Enliven Therapeutics stock By Investing.com
OrbiMed Advisors LLC and its affiliated entities sold approximately $12.7 million worth of Enliven Therapeutics (NASDAQ:ELVN) common stock on June 15, 2026, at a price of $45.02 per share. This sale occurred while Enliven's stock was trading near its 52-week high, following significant year-to-date gains. The biotech company has recently seen an upsized public offering and positive Phase 1 clinical trial results for its leukemia drug candidate, ELVN-001.
Enliven Therapeutics Inc (ELVN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Enliven Therapeutics Inc (ELVN) regarding its dividend history and stock split events. It indicates that ELVN has distributed no dividends in the past five years. The company experienced a 4-for-1 merger-related stock split on February 23, 2023.
Enliven Therapeutics (ELVN) affiliate notifies broker to offer 18,054 shares
Enliven Therapeutics filed a Form 144 to report the proposed sale of 18,054 shares of Common Stock through Jefferies LLC, dated June 17, 2026. The shares are tied to three separate option exercises from August 2022, December 2024, and March 2025, with an aggregate value of $768,197.70 listed on the cover. This filing is a routine notice for the resale of shares previously acquired through option exercises and does not yet confirm actual sales or proceeds.
Ex-Genentech exec moves Boulder biotech to Bay Area with $400 million in the bank
Enliven Therapeutics, a Boulder-based biotech company, is relocating its headquarters to the Bay Area after raising $400 million. The company, led by CEO Rick Fair, is developing treatments for chronic myeloid leukemia, competing with pharmaceutical giants Novartis and Merck.
Former Genentech exec moves company to Bay Area from Colorado with $400 million in the bank
Former Genentech executive Rick Fair has moved his company, Enliven Therapeutics, to the Bay Area from Colorado. The company, which Fair joined as CEO in December, has secured $400 million in funding. Enliven Therapeutics is focused on developing treatments for chronic myeloid leukemia and is competing with major pharmaceutical companies in this space.
Biotech Enliven just raised $460M in stock and warrants
Enliven Therapeutics announced the closing of an upsized underwritten public offering, raising approximately $460 million in gross proceeds from the sale of common stock and pre-funded warrants. The offering included the full exercise of the underwriters' option to purchase additional shares. This financing follows recent positive clinical data, aiming to resource the company's development plans while also leading to dilution for existing shareholders.
[144] Enliven Therapeutics, Inc. SEC Filing
This article details an SEC Form 144 filing by Enliven Therapeutics, Inc. (ELVN) concerning the proposed sale of securities. The document provides information about the filer, the issuer, the class of securities to be sold (Common Stock), along with details of their acquisition, and confirms no securities were sold in the past three months by the person filing. It highlights the company's recent news, including a public offering and clinical data updates.
Enliven Therapeutics closes $460M public offering
Enliven Therapeutics Inc. (NASDAQ:ELVN) successfully completed an upsized public offering, raising approximately $460 million. The company sold over 10.5 million shares of common stock and pre-funded warrants, with the stock closing 13% above the offering price. This funding follows recent positive trial data for its leukemia drug candidate ELVN-001 and favorable analyst coverage.
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics (Nasdaq: ELVN) announced the pricing of an upsized underwritten public offering of 8,933,334 shares of its common stock at $37.50 per share, and pre-funded warrants for up to 1,733,333 shares at $37.499 per warrant. The offering is expected to generate approximately $400.0 million in gross proceeds and is slated to close around June 15, 2026. Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays are acting as joint book-running managers for the offering.
Enliven Therapeutics, Inc. (ELVN) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow
Enliven Therapeutics, Inc. (ELVN) presented a slide deck at the European Hematology Association (EHA) 2026 Congress. The presentation was published on June 15, 2026. This article was created by Seeking Alpha's transcripts team.
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics, Inc. (Nasdaq: ELVN) has announced the closing of its upsized public offering, raising approximately $460.0 million before deductions. The offering included 10,533,334 shares of common stock at $37.50 per share and pre-funded warrants for 1,733,333 shares at $37.499 per warrant, with the underwriters fully exercising their option for additional shares. The proceeds will support the company's focus on discovering and developing small molecule therapeutics.
Enliven Therapeutics reports positive phase 1 CML data and FDA alignment for phase 3 trial (ELVN)
The article reports that Enliven Therapeutics has announced positive Phase 1 clinical trial data for its chronic myeloid leukemia (CML) treatment. The company has also reached alignment with the FDA regarding the design of its upcoming Phase 3 trial. This news likely signals progress in the development of ELVN's CML drug candidate.
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial
Enliven Therapeutics (ELVN) saw its stock price surge by 14.30 percent after releasing positive results from the first phase of its clinical trial for the experimental leukemia drug, ELVN-001. The trial indicated that 40% of patients achieved a major molecular response, with 48% in the 80 mg dose group, suggesting significant reduction in leukemia levels. The company's Chief Medical Officer highlighted the drug's potential as a "best-in-class" inhibitor and announced alignment with the FDA on the Phase 3 trial design.
Enliven Therapeutics Prices $400 Million Public Offering
Enliven Therapeutics has priced a public offering of 33,333,334 shares of its common stock at $12.00 per share, aiming to raise $400 million before underwriting discounts and expenses. This offering is expected to close on June 17, 2026, subject to customary closing conditions. J.P. Morgan, Goldman Sachs & Co. LLC, and Leerink Partners are acting as joint book-running managers.
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial
Enliven Therapeutics (ELVN) saw its stock price climb significantly after reporting encouraging results from its ELVN-001 leukemia drug trial. The first phase of the clinical trial showed a 40% major molecular response rate among patients, with an even higher rate of 48% in the 80 mg dose group, indicating strong potential for the drug. The company is advancing towards a Phase 3 trial later this year after aligning with the FDA on dosage and patient inclusion.
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial
Enliven Therapeutics (ELVN) saw its stock price climb significantly after reporting encouraging results from the first phase of its clinical trial for the experimental leukemia drug, ELVN-001. The trial showed that 40% of patients achieved a major molecular response, with higher response rates in the 80 mg dose group and earlier lines of therapy. The company has also reached an agreement with the FDA on the 80 mg dose and patient inclusion for the upcoming ENABLE-2 Phase 3 trial.
Enliven Therapeutics (NASDAQ: ELVN) raises $376M via 8.93M-share offering
Enliven Therapeutics (NASDAQ: ELVN) is raising approximately $376 million through an offering of 8.93 million shares of common stock and pre-funded warrants for 1.73 million shares at $37.50 per share. The proceeds are intended to fund the clinical development of ELVN-001, including the initiation of a planned Phase 3 trial (ENABLE-2) in the second half of 2026, and to extend the company's operational runway into 2030. The offering also provides an option for underwriters to purchase an additional 1.6 million shares, which could increase net proceeds to $432.4 million.
Enliven Therapeutics Prices ~$376 Million Equity Offering; Jefferies, Goldman, Morgan Stanley Lead
Enliven Therapeutics has priced an equity offering expected to raise approximately $376.0 million, or up to $432.4 million if the underwriters' option is fully exercised. The offering includes 8,933,334 shares at $37.50 each and 1,733,333 pre-funded warrants at $37.499, with Jefferies, Goldman Sachs, and Morgan Stanley leading the underwriting. The capital is intended to fund the company's operations and development programs, with closing anticipated on June 15, 2026.
Enliven Therapeutics (Nasdaq: ELVN) plans $400M stock and warrant sale
Enliven Therapeutics (Nasdaq: ELVN) has priced an upsized underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $400 million in gross proceeds. The offering includes 8,933,334 shares of common stock at $37.50 per share and 1,733,333 pre-funded warrants at $37.499 each, with an option for underwriters to purchase an additional 1,600,000 shares. This capital raise is intended to provide new funds directly to the company, with the closing expected around June 15, 2026.
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)
LifeSci Capital reiterated a Buy rating on Enliven Therapeutics (ELVN) with a $60.00 price target, highlighting the company's Strong Buy consensus among analysts. Meanwhile, JonesTrading maintained a Hold rating on Oncolytics Biotech (ONCY), despite its Strong Buy analyst consensus and significant upside potential.
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise
Enliven Therapeutics Inc. (ELVN) stock surged about 15.77% following promising Phase 1 ENABLE data for its ELVN-001 drug in CML patients and FDA alignment for a Phase 3 trial. The company also announced an upsized offering of shares and warrants, raising approximately $400 million. Analysts from Stifel and Mizuho have issued Buy/Outperform ratings with price targets significantly above current levels, driven by the drug's potential and the company's strengthened financial position.
Enliven Therapeutics launches $250M stock offering
Enliven Therapeutics (NASDAQ:ELVN) has announced an underwritten public offering of $250 million in common stock and pre-funded warrants, with an option for underwriters to purchase an additional $37.5 million. This announcement follows positive results from its Phase 1 ENABLE trial for leukemia drug candidate ELVN-001, which spurred analyst upgrades from Stifel and Mizuho. The company plans to further discuss trial data on June 11, 2026, at the European Hematology Association Congress.
Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants
Enliven Therapeutics has priced an upsized public offering, raising $400 million through the sale of common stock and pre-funded warrants. This financial move aims to secure capital for the company's operations and potentially advance its therapeutic pipeline. The offering reflects investor interest in Enliven Therapeutics' future prospects.
